Asociación para Evitar la Ceguera en México [clinicaltrials_resource:d438ba1ad7cb641aa468027edbddc89e]
Hugo Quiroz-Mercado, MD [clinicaltrials_resource:0084a5253e4b4f47cdde14e08df7ec05]Antonio Pellicer, MDPhD [clinicaltrials_resource:04d4442faff5f7e35e194ccdd801cc11]Veronica Kon-Jara, MD [clinicaltrials_resource:10c54e1e11d991af28ba38d888d868c4]Gerardo García-Aguirre, MD [clinicaltrials_resource:12c30709c1765529e1cb7e7142a1d091]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Adriana Solís-Vivanco, MD [clinicaltrials_resource:160e2b88198a677fbecf310522bccfd0]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:1b050990787dc1655152229fb7c3c93e]Gerardo García-Aguirre, MD [clinicaltrials_resource:20af2cf4c938890f2e4b7bd8fedc8af4]Maria A Martinez-Castellanos, MD [clinicaltrials_resource:26e31e80409666bdce35766dfc6bf8f4]Guillermo Salcedo, M.D. [clinicaltrials_resource:2a1f80e4749c8e18fb9138115859afff]Gerardo García-Aguirre, MD [clinicaltrials_resource:4390509a72c3528dccc54f092d4f4399]Veronica Kon-Jara, MD [clinicaltrials_resource:4c2d5d039441ace9177e520acd4d52cb]Myrian L Hernández, MD [clinicaltrials_resource:4c9affa977bf0a274302430d5eb4b647]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:5276cd3d290d87789b8d54c529d5540f]Gerardo García-Aguirre, MD [clinicaltrials_resource:5d120154d7aa9b17f23a97b9b242c6bd]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:6cf8ce8d318cc8ab31fc16ea8dc89064]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:7aaf9e18e5a163157e993b7ca624994f]Veronica Kon-Jara, MD [clinicaltrials_resource:85a6cd9ed208fea82444e77792a1de00]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:9206900d2cf09aff787ebee8d026505f]Maria A Martinez-Castellanos, MD [clinicaltrials_resource:927f4ee32c2579fc78b29328505032ef]Veronica Kon-Jara, MD [clinicaltrials_resource:9424b53c5e309b417e62ff3c430471d7]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:94672bbc403d7e917eec565316ce7a35]Veronica Kon-Jara, MD [clinicaltrials_resource:a5545e41f6bf6ed23d5820f5ab4b25da]Veronica Kon-Jara, MD [clinicaltrials_resource:ab3755dd7024af2f20872aad8b86d112]Gerardo García-Aguirre, MD [clinicaltrials_resource:ad55e59a4bc5d68f6936b85459f5f71d]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:b31806de5ab6b87b5580c710c1daa317]Gerardo García-Aguirre, MD [clinicaltrials_resource:b8c2f0845056aa4bbf84f210cf4d4965]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:bc8deba253c7286f05ae306db26a69b3]Gerardo García-Aguirre, MD [clinicaltrials_resource:bfcc548651bcb31bd81d6b43f8b5b766]Veronica Kon-Jara, MD [clinicaltrials_resource:c992aa0cfe2994a4387d5c7f94451282]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:cf244520fd2288317f604edf7b1a4b57]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:d414f4545c20375c9aeef3239cc146a0]Veronica Kon-Jara, MD [clinicaltrials_resource:d549cbc796b315c7fa383339b60ed70f]Maria A Martinez-Castellanos, MD [clinicaltrials_resource:d7215dc96a3dd61b601d6a1b959dd2ed]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:e192a0deca321ab371173625920bbb8f]Eduarto Torres-Porras, MD [clinicaltrials_resource:e9b91bf5b3cef78a4ed20475908654e3]Gerardo García-Aguirre, MD [clinicaltrials_resource:ee0d0dd9ecc125941e35b0dc995e2a06]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:f004d68cb81437833a8edd202f87d959]Hugo Quiroz-Mercado, MD [clinicaltrials_resource:f8810c47b12f8437d6c7027484fa760b]Oscar Alvarez-Verduzco, MD [clinicaltrials_resource:fa077d8fcb17a3eac25c1a16933479a5]
affiliation [clinicaltrials_vocabulary:affiliation]
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization [clinicaltrials:NCT00555594]Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut [clinicaltrials:NCT00558324]HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population [clinicaltrials:NCT00600236]Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization [clinicaltrials:NCT00930189]
collaborator [clinicaltrials_vocabulary:collaborator]
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome [clinicaltrials:NCT00346814]Intravitreal Bevacizumab for Age-Related Macular Degeneration [clinicaltrials:NCT00347165]Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration [clinicaltrials:NCT00347399]Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy [clinicaltrials:NCT00347698]Bevacizumab and Retinal Vascular Occlusions [clinicaltrials:NCT00347711]Comparison High-Density Silicone Oils in Retinal Detachment [clinicaltrials:NCT00403702]Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment [clinicaltrials:NCT00404209]Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) [clinicaltrials:NCT00406172]Effect of Avastin in Juxtafoveal Telangiectasias [clinicaltrials:NCT00406380]Efficacy of Retreatments With Intravitreal Bevacizumab [clinicaltrials:NCT00406744]Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy [clinicaltrials:NCT00407108]Intravitreal Bevacizumab for Inflammatory Neovascular Membranes [clinicaltrials:NCT00407121]Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema [clinicaltrials:NCT00417716]Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment [clinicaltrials:NCT00417833]Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy [clinicaltrials:NCT00418431]Unilateral Bevacizumab for Bilateral Diabetic Macular Edema [clinicaltrials:NCT00496405]A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis [clinicaltrials:NCT00499551]Vascular Endothelial Growth Factor in Stage V ROP [clinicaltrials:NCT00500396]Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization [clinicaltrials:NCT00555594]Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut [clinicaltrials:NCT00558324]Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment [clinicaltrials:NCT00563043]VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V [clinicaltrials:NCT00563121]Changes in Macular Thickness After Patterns Scan Laser [clinicaltrials:NCT00563628]Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO [clinicaltrials:NCT00566761]POSTERIOR SUB-TENON'S Avastin [clinicaltrials:NCT00567372]Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema [clinicaltrials:NCT00571142]Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma. [clinicaltrials:NCT00599690]Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks [clinicaltrials:NCT00599820]Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C [clinicaltrials:NCT00599950]HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population [clinicaltrials:NCT00600236]Intravitreal Bevacizumab for Diabetic Retinopathy [clinicaltrials:NCT00600262]Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study [clinicaltrials:NCT00600301]Avastin for Post-Photocoagulation Macular Edema [clinicaltrials:NCT00801866]clinicaltrials:NCT00801905Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. [clinicaltrials:NCT00802269]The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform [clinicaltrials:NCT00802698]PASCAL: Safety and Complications, Experience After 1301 Consecutive Cases [clinicaltrials:NCT00803153]Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation [clinicaltrials:NCT00804206]PASCAL Trabeculoplasty [clinicaltrials:NCT00804323]A-Mode vs PalmScan Ultrasonography: Biometric Measurements. [clinicaltrials:NCT00804869]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Oscar Alvarez-Verduzco, Asociación para Evitar la Ceguera en México [clinicaltrials_resource:3cec912ecb3de57b79fe19477b3f7e15]Asociación para Evitar la Ceguera en México, Asociación para Evitar la Ceguera en México [clinicaltrials_resource:4cf3569aa295f83871f5f4fc5d3d1da3]Maria Ana Martínez Castellanos MD, Asociación para Evitar la Ceguera en México [clinicaltrials_resource:50f85a5e9e97fac35b5c40d5a9e85ed2]
organization [clinicaltrials_vocabulary:organization]
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome [clinicaltrials:NCT00346814]Intravitreal Bevacizumab for Age-Related Macular Degeneration [clinicaltrials:NCT00347165]Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration [clinicaltrials:NCT00347399]Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy [clinicaltrials:NCT00347698]Bevacizumab and Retinal Vascular Occlusions [clinicaltrials:NCT00347711]Comparison High-Density Silicone Oils in Retinal Detachment [clinicaltrials:NCT00403702]Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment [clinicaltrials:NCT00404209]Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) [clinicaltrials:NCT00406172]Effect of Avastin in Juxtafoveal Telangiectasias [clinicaltrials:NCT00406380]Efficacy of Retreatments With Intravitreal Bevacizumab [clinicaltrials:NCT00406744]Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy [clinicaltrials:NCT00407108]Intravitreal Bevacizumab for Inflammatory Neovascular Membranes [clinicaltrials:NCT00407121]Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema [clinicaltrials:NCT00417716]Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment [clinicaltrials:NCT00417833]Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy [clinicaltrials:NCT00418431]Unilateral Bevacizumab for Bilateral Diabetic Macular Edema [clinicaltrials:NCT00496405]A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis [clinicaltrials:NCT00499551]Vascular Endothelial Growth Factor in Stage V ROP [clinicaltrials:NCT00500396]Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization [clinicaltrials:NCT00555594]Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut [clinicaltrials:NCT00558324]Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment [clinicaltrials:NCT00563043]VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V [clinicaltrials:NCT00563121]Changes in Macular Thickness After Patterns Scan Laser [clinicaltrials:NCT00563628]Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO [clinicaltrials:NCT00566761]POSTERIOR SUB-TENON'S Avastin [clinicaltrials:NCT00567372]Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema [clinicaltrials:NCT00571142]Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma. [clinicaltrials:NCT00599690]Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks [clinicaltrials:NCT00599820]Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C [clinicaltrials:NCT00599950]HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population [clinicaltrials:NCT00600236]Intravitreal Bevacizumab for Diabetic Retinopathy [clinicaltrials:NCT00600262]Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study [clinicaltrials:NCT00600301]Avastin for Post-Photocoagulation Macular Edema [clinicaltrials:NCT00801866]clinicaltrials:NCT00801905Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. [clinicaltrials:NCT00802269]The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform [clinicaltrials:NCT00802698]PASCAL: Safety and Complications, Experience After 1301 Consecutive Cases [clinicaltrials:NCT00803153]Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation [clinicaltrials:NCT00804206]PASCAL Trabeculoplasty [clinicaltrials:NCT00804323]A-Mode vs PalmScan Ultrasonography: Biometric Measurements. [clinicaltrials:NCT00804869]
source [clinicaltrials_vocabulary:source]
Asociación para Evitar la Ceguera en México [clinicaltrials_resource:d438ba1ad7cb641aa468027edbddc89e]
Bio2RDF identifier
d438ba1ad7cb641aa468027edbddc89e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d438ba1ad7cb641aa468027edbddc89e
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:d438ba1ad7cb641aa468027edbddc89e
title
Asociación para Evitar la Ceguera en México
@en
type
label
Asociación para Evitar la Cegu ...... 8ba1ad7cb641aa468027edbddc89e]
@en